• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Rapport Therapeutics Inc.

    4/24/25 6:08:54 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RAPP alert in real time by email
    DEFA14A 1 d940377ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    RAPPORT THERAPEUTICS, INC.

    (Name of Registrant as Specified in Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) Exchange Act Rules 14a-6(i)(1) and 0-11

     

     
     


     

     

     

      LOGO

    RAPPORT THERAPEUTICS, INC.

    1325 BOYLSTON STREET, SUITE 401

    BOSTON, MA 02215

     

     

    V68858-P24981

     

     

     

    LOGO

     

    You invested in RAPPORT THERAPEUTICS, INC. and it’s time to vote!

    You have the right to vote on proposals being presented at the 2025 Annual Meeting, which is being held virtually. Important Notice Regarding the Availability of Proxy Materials for the 2025 Annual Meeting of Stockholders to be Held on June 17, 2025.

    Get informed before you vote

    View the Notice, Proxy Statement and 2024 Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 3, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

     

      LOGO

     

    Smartphone users       LOGO   

    Vote Virtually at the Meeting*

     

    Point your camera here and

    vote without entering a

    control number

          June 17, 2025
          9:30 AM ET
         

      LOGO

           Virtually at:
           www.virtualshareholdermeeting.com/RAPP2025
            
              

     

     

    *Please check the meeting materials for any special requirements for meeting attendance.


    Vote at www.ProxyVote.com

     

     

    THIS IS NOT A VOTABLE BALLOT

    This is an overview of the proposals being presented at the

    upcoming 2025 Annual Meeting. Please follow the instructions

    on the reverse side to vote on these important matters.

     

     Voting Items

     

     

    Board

    Recommends

     

    1.

      To elect Reid Huber, Ph.D., John Maraganore, Ph.D., and Wendy B. Young, Ph.D. as Class I Directors.  
     
      Nominees:  
     
       

    01)  Reid Huber, Ph.D.

    02)  John Maraganore, Ph.D.

    03)  Wendy B. Young, Ph.D.

      LOGO  For
     

    2.

      To ratify the appointment of PricewaterhouseCoopers LLP as Rapport’s independent registered public accounting firm for the fiscal year ending December 31, 2025.  

    LOGO  For

    NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any continuations, adjournments and postponements thereof.

       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
        
       
       
       

     

    Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.

    V68859-P24981

    Get the next $RAPP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RAPP

    DatePrice TargetRatingAnalyst
    4/8/2025Mkt Outperform
    Citizens JMP
    7/2/2024Buy
    TD Cowen
    7/2/2024$35.00Buy
    Jefferies
    7/2/2024$35.00Buy
    Stifel
    More analyst ratings

    $RAPP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates

      BOSTON and SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today will host its inaugural Investor and Analyst Day, featuring presentations from Rapport's executive team on the Company's strategic priorities and updates from its clinical pipeline, including progress on the RAP-219 Phase 2a trial in focal epilepsy. The event's agenda also includes a fireside chat with key opinion leader and professor of Neurology at NYU Langone's Comprehensive Epileps

      6/2/25 2:45:00 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference

      BOSTON and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in two upcoming investor conferences. Jefferies Global Healthcare Conference (New York City) - fireside chat on Wednesday, June 4, 2025, at 10:30 a.m. Eastern Time. Goldman Sachs 46th Annual Global Healthcare Conference 2025 (Miami, FL) - fireside chat on Monday, June 9, 2025, at 10:00 a.m. Eastern Time. Interested parties may access the live and archived webc

      5/27/25 7:00:00 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rapport Therapeutics to Host 2025 Investor and Analyst Day

      BOSTON and SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced it will host its inaugural Investor and Analyst Day on Monday, June 2, 2025, in New York City. The event will also be webcast live. Rapport senior management will review the company's clinical programs, with a focus on the RAP-219 Phase 2a trial in refractory focal epilepsy. The event will also feature a fireside chat with Dr. Jacqueline A. French—a globally recognized leader in epilepsy research, profes

      5/21/25 7:00:00 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RAPP
    SEC Filings

    See more
    • Rapport Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)

      6/2/25 4:07:20 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Rapport Therapeutics Inc.

      10-Q - Rapport Therapeutics, Inc. (0002012593) (Filer)

      5/8/25 7:30:23 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rapport Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)

      5/8/25 7:15:09 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RAPP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Bredt David sold $81,262 worth of shares (8,500 units at $9.56), decreasing direct ownership by 2% to 452,142 units (SEC Form 4)

      4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

      5/19/25 4:30:28 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Bredt David sold $81,310 worth of shares (8,500 units at $9.57), decreasing direct ownership by 2% to 460,642 units (SEC Form 4)

      4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

      4/16/25 5:00:04 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Sevigny Jeffrey

      4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

      4/3/25 5:00:07 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RAPP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Ignelzi Troy A. bought $100,988 worth of shares (10,000 units at $10.10) (SEC Form 4)

      4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

      3/13/25 5:13:57 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Young Wendy B. bought $61,250 worth of shares (6,000 units at $10.21) (SEC Form 4)

      4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

      3/13/25 5:00:03 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Healy James bought $1,079,575 worth of shares (44,032 units at $24.52) (SEC Form 4)

      4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

      7/3/24 8:04:04 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RAPP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Rapport Therapeutics Inc.

      SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

      11/14/24 5:13:31 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rapport Therapeutics Inc.

      SC 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)

      11/14/24 3:11:15 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Rapport Therapeutics Inc.

      SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

      11/13/24 12:26:41 PM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RAPP
    Leadership Updates

    Live Leadership Updates

    See more
    • Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS) disorders Continued momentum in the Phase 2a trial of RAP-219 in patients with refractory focal epilepsy, with topline results expected in the third quarter of 2025Expect to initiate a Phase 2a trial in patients with bipolar mania in the third quarter of 2025, with topline results expected in the first half of 2027  Appointed recognized translational and clinical drug development leader, Jeffrey Sevigny, M.D., as chief medical officer  Ended the year with $305.3 million in cash, cash equivalents, an

      3/11/25 7:00:00 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

      BOSTON and SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced the appointment of Dr. Jeffrey Sevigny as chief medical officer (CMO), effective immediately. A physician-scientist with more than 15 years of leadership in translational and clinical drug development, Dr. Sevigny has spearheaded groundbreaking research across neuroscience and rare diseases. His experience spans the full spectrum of development, from discovery to late-stage clinical trials an

      3/3/25 7:00:00 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update

      Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and operational leadershipRAP-219 MAD-2 and PET trials ongoing; topline data expected in Q1 2025Actively recruiting patients for Phase 2a trial of RAP-219 in focal epilepsy; trial on track and topline data expected in mid-2025 Investigational New Drug Application (IND) in diabetic peripheral neuropathic pain placed on clinical hold while the Company addresses U.S. Food and Drug Administration (FDA) Phase 2a trial protocol feedback Ended the quarter with $320.7 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is

      11/7/24 7:00:00 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RAPP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citizens JMP initiated coverage on Rapport Therapeutics

      Citizens JMP initiated coverage of Rapport Therapeutics with a rating of Mkt Outperform

      4/8/25 9:31:03 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on Rapport Therapeutics

      TD Cowen initiated coverage of Rapport Therapeutics with a rating of Buy

      7/2/24 8:03:15 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Rapport Therapeutics with a new price target

      Jefferies initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $35.00

      7/2/24 7:51:37 AM ET
      $RAPP
      Biotechnology: Pharmaceutical Preparations
      Health Care